Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B

BACKGROUND: Various treatment combinations of peginterferon (PEG‐IFN) and nucleos(t)ide analogues have been evaluated for chronic hepatitis B (CHB), but the optimal regimen remains unclear. AIMS: To study whether PEG‐IFN add‐on increases response compared to entecavir (ETV) monotherapy, and whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Liem, Kin Seng, van Campenhout, Margo J. H., Xie, Qing, Brouwer, Willem Pieter, Chi, Heng, Qi, Xun, Chen, Liang, Tabak, Fehmi, Hansen, Bettina E., Janssen, Harry L. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Hepb Sag and Hbv DNA Predict Response to Pegylated Interferon plus Entecavir
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590282/
https://www.ncbi.nlm.nih.gov/pubmed/30689258
http://dx.doi.org/10.1111/apt.15098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590282/
https://www.ncbi.nlm.nih.gov/pubmed/30689258
http://dx.doi.org/10.1111/apt.15098

Ejemplares similares